Merck Nears $6B Deal to Acquire Terns Pharmaceuticals

Key Deal Highlights

Merck & Company is reportedly nearing a deal to acquire Terns Pharmaceuticals for approximately $6 billion. The all-cash transaction is expected to value Terns at a premium to its current market capitalization of about $5.3 billion and could be finalized in the coming days.

Strategic Pipeline Enhancement

This potential acquisition is a strategic move by Merck to strengthen its product pipeline. The company faces the looming patent expiry of its blockbuster cancer drug, Keytruda, which generates around $30 billion in annual revenue and could lose exclusivity as early as 2028. Terns' lead asset is a treatment for chronic myeloid leukaemia CML, a rare blood and bone marrow cancer.

Market Impact and Context

The deal reflects Merck's accelerated M&A strategy to offset future revenue losses. The company has been actively making deals, including last year's acquisitions cited in reports, to demonstrate its commitment to expanding its portfolio through strategic buyouts and secure future growth drivers.

Summary and Outlook

The acquisition of Terns Pharmaceuticals would significantly bolster Merck's oncology division and address concerns about the Keytruda patent cliff. Investors will be watching for the final announcement and how the new assets are integrated into Merck's long-term growth strategy.

FAQ

Q: Why is Merck acquiring Terns Pharmaceuticals?
A: Merck aims to strengthen its drug pipeline ahead of the patent expiry for its leading cancer drug, Keytruda, which is expected around 2028.

Q: What is the reported value of the acquisition?
A: The all-cash deal is valued at approximately $6 billion.

Source: Financial Times via Investing.com